Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in sustainable pharmaceutical manufacturing, provided a corporate update on January 26, 2026, summarizing its 2025 progress and outlining strategic objectives for 2026. The company also confirmed plans for a pending name change to Quantum Genesis AI Corp. and a corresponding trading symbol change, subject to regulatory approvals.
During 2025, Quantumzyme focused on foundational research in enzyme engineering and biocatalytic process development for pharmaceutical and specialty chemical applications. The company advanced its regulatory reporting practices, published U.S. and international patent applications for enzymatic processes, and updated its corporate communications to clarify its business focus. Additionally, Quantumzyme began integrating artificial intelligence and computational methods into its research workflow, evaluating machine learning and computational modeling to support enzyme discovery and structure-function analysis. These AI initiatives remain at a research stage, intended to enhance experimental design and data analysis efficiency.
The Board of Directors approved a proposal to change the company's legal name to Quantum Genesis AI Corp., reflecting an increased emphasis on computational and data-driven approaches. The name and symbol change are expected to be completed in the first quarter of 2026, pending FINRA approval and other regulatory requirements. For more information, visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
Looking ahead to 2026, Quantumzyme outlined key priorities: advancing enzyme candidates and biocatalytic pathways through internal testing; refining computational modeling and AI tools; exploring potential collaborations with pharmaceutical and chemical industry participants; increasing visibility through scientific forums and investor communications; and assessing long-term corporate objectives including reporting status and capital planning. The company cautioned that these objectives are subject to risks such as technical challenges, capital availability, and market conditions.
Quantumzyme's focus on integrating AI into enzyme research positions it to potentially improve industrial sustainability through scalable biocatalysis solutions. However, as an early-stage biotechnology company, its developments remain exploratory, and there is no assurance of commercial success or patent grants.
